...
search icon
fulc-img

Fulcrum Therapeutics Inc, Common Stock

FULC

NMQ

$4.015

+$0.16

(4.16%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$193.79M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
107.28K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.13
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.31 L
$10.13 H
$4.015

About Fulcrum Therapeutics Inc, Common Stock

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial. It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameFULCSectorS&P500
1-Week Return7.24%3.49%3.59%
1-Month Return33.68%-3.79%-0.81%
3-Month Return-7.89%-4.66%-8.37%
6-Month Return18.83%-5.16%-4.39%
1-Year Return-46%0.1%10.47%
3-Year Return-60.71%8.49%33.76%
5-Year Return-69.49%40.85%90.84%
10-Year Return-71.48%95.89%166.74%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue8.82M19.16M6.34M2.81M80.00M[{"date":"2020-12-31","value":11.03,"profit":true},{"date":"2021-12-31","value":23.95,"profit":true},{"date":"2022-12-31","value":7.93,"profit":true},{"date":"2023-12-31","value":3.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue2.38M2.52M2.41M71.80M-[{"date":"2020-12-31","value":3.31,"profit":true},{"date":"2021-12-31","value":3.5,"profit":true},{"date":"2022-12-31","value":3.36,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit8.82M19.16M3.93M2.81M80.00M[{"date":"2020-12-31","value":11.03,"profit":true},{"date":"2021-12-31","value":23.95,"profit":true},{"date":"2022-12-31","value":4.91,"profit":true},{"date":"2023-12-31","value":3.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%61.94%100.00%100.00%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":61.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses80.43M100.22M118.48M113.47M101.90M[{"date":"2020-12-31","value":67.89,"profit":true},{"date":"2021-12-31","value":84.59,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.77,"profit":true},{"date":"2024-12-31","value":86.01,"profit":true}]
Operating Income(71.61M)(81.05M)(112.56M)(110.66M)(21.90M)[{"date":"2020-12-31","value":-7161100000,"profit":false},{"date":"2021-12-31","value":-8105400000,"profit":false},{"date":"2022-12-31","value":-11256100000,"profit":false},{"date":"2023-12-31","value":-11066400000,"profit":false},{"date":"2024-12-31","value":-2189700000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(70.82M)(80.85M)(109.87M)(97.33M)(9.72M)[{"date":"2020-12-31","value":-7081900000,"profit":false},{"date":"2021-12-31","value":-8084700000,"profit":false},{"date":"2022-12-31","value":-10987100000,"profit":false},{"date":"2023-12-31","value":-9733500000,"profit":false},{"date":"2024-12-31","value":-972500000,"profit":false}]
Income Taxes(2.38M)(2.52M)(4.25M)2.00M-[{"date":"2020-12-31","value":-118.71,"profit":false},{"date":"2021-12-31","value":-125.49,"profit":false},{"date":"2022-12-31","value":-212.06,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(70.82M)(80.85M)(109.87M)(98.71M)(9.72M)[{"date":"2020-12-31","value":-7081900000,"profit":false},{"date":"2021-12-31","value":-8084700000,"profit":false},{"date":"2022-12-31","value":-10987100000,"profit":false},{"date":"2023-12-31","value":-9871400000,"profit":false},{"date":"2024-12-31","value":-972500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(68.44M)(78.33M)(105.62M)(97.33M)(9.72M)[{"date":"2020-12-31","value":-6844000000,"profit":false},{"date":"2021-12-31","value":-7833200000,"profit":false},{"date":"2022-12-31","value":-10562100000,"profit":false},{"date":"2023-12-31","value":-9733500000,"profit":false},{"date":"2024-12-31","value":-972500000,"profit":false}]
EPS (Diluted)(2.81)(2.29)(2.48)(1.58)(0.33)[{"date":"2020-12-31","value":-281,"profit":false},{"date":"2021-12-31","value":-229,"profit":false},{"date":"2022-12-31","value":-248,"profit":false},{"date":"2023-12-31","value":-158,"profit":false},{"date":"2024-12-31","value":-33.33,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

FULC
Cash Ratio 21.82
Current Ratio 22.63

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

FULC
ROA (LTM) -4.78%
ROE (LTM) -4.07%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

FULC
Debt Ratio Lower is generally better. Negative is bad. 0.07
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.93

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

FULC
Trailing PE NM
Forward PE NM
P/S (TTM) 2.41
P/B 0.79
Price/FCF NM
EV/R 117.40
EV/Ebitda NM

FAQs

What is Fulcrum Therapeutics Inc share price today?

Fulcrum Therapeutics Inc (FULC) share price today is $4.015

Can Indians buy Fulcrum Therapeutics Inc shares?

Yes, Indians can buy shares of Fulcrum Therapeutics Inc (FULC) on Vested. To buy Fulcrum Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FULC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Fulcrum Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Fulcrum Therapeutics Inc (FULC) via the Vested app. You can start investing in Fulcrum Therapeutics Inc (FULC) with a minimum investment of $1.

How to invest in Fulcrum Therapeutics Inc shares from India?

You can invest in shares of Fulcrum Therapeutics Inc (FULC) via Vested in three simple steps:

  • Click on Sign Up or Invest in FULC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Fulcrum Therapeutics Inc shares
What is Fulcrum Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Fulcrum Therapeutics Inc (FULC) is $10.13. The 52-week low price of Fulcrum Therapeutics Inc (FULC) is $2.31.

What is Fulcrum Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Fulcrum Therapeutics Inc (FULC) is 0.79

What is the Market Cap of Fulcrum Therapeutics Inc?

The market capitalization of Fulcrum Therapeutics Inc (FULC) is $193.79M

What is Fulcrum Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Fulcrum Therapeutics Inc is FULC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top